- Home
- UMAC vs GLSI Comparison
UMAC vs GLSI Comparison
Compare UMAC & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMAC
- GLSI
- Stock Information
- Founded
- UMAC 2019
- GLSI 2006
- Country
- UMAC United States
- GLSI United States
- Employees
- UMAC N/A
- GLSI N/A
- Industry
- UMAC
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- UMAC
- GLSI Health Care
- Exchange
- UMAC Nasdaq
- GLSI Nasdaq
- Market Cap
- UMAC 134.1M
- GLSI 133.4M
- IPO Year
- UMAC 2024
- GLSI 2020
- Fundamental
- Price
- UMAC $8.16
- GLSI $9.88
- Analyst Decision
- UMAC Strong Buy
- GLSI Strong Buy
- Analyst Count
- UMAC 2
- GLSI 1
- Target Price
- UMAC $19.00
- GLSI $39.00
- AVG Volume (30 Days)
- UMAC 6.1M
- GLSI 40.0K
- Earning Date
- UMAC 08-13-2025
- GLSI 08-13-2025
- Dividend Yield
- UMAC N/A
- GLSI N/A
- EPS Growth
- UMAC N/A
- GLSI N/A
- EPS
- UMAC N/A
- GLSI N/A
- Revenue
- UMAC $6,988,704.00
- GLSI N/A
- Revenue This Year
- UMAC $160.90
- GLSI N/A
- Revenue Next Year
- UMAC $135.75
- GLSI N/A
- P/E Ratio
- UMAC N/A
- GLSI N/A
- Revenue Growth
- UMAC 1029.19
- GLSI N/A
- 52 Week Low
- UMAC $1.13
- GLSI $8.06
- 52 Week High
- UMAC $23.62
- GLSI $18.15
- Technical
- Relative Strength Index (RSI)
- UMAC 53.87
- GLSI 61.53
- Support Level
- UMAC $7.55
- GLSI $8.97
- Resistance Level
- UMAC $8.91
- GLSI $9.19
- Average True Range (ATR)
- UMAC 1.07
- GLSI 0.35
- MACD
- UMAC -0.14
- GLSI 0.07
- Stochastic Oscillator
- UMAC 18.89
- GLSI 99.20
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.